Speaker Profile

Ph.D., CTO, BillionToOne Inc.

At BillionToOne, David co-developed the molecular counter platform that increases the resolution of cell-free DNA diagnostics by over a thousand-fold. This technology was used to develop BillionToOne’s single-gene NIPT, which is the only (and fastest-growing) test that can detect the most common inherited disorders such as sickle cell disease, cystic fibrosis, and spinal muscular atrophy in the fetus directly from maternal blood. David is the co-founder and CTO at BillionToOne. He was the lead author of BillionToOne's foundational patents and single-gene NIPT clinical trial, which was published in Nature Scientific Reports. His work has been supported by the NHLBI of the National Institutes of Health. Previously, David received his PhD in Bioengineering from Rice University. He graduated cum laude from Princeton University with a Bachelor’s in Physics and minors in Biophysics and Engineering & Management Systems.

Clinical Dx Showcase:
BillionToOne Inc.

BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more powerful, accurate, and accessible for all. Our QCT molecular counting platform enables us to offer unique products from single-gene NIPT to quantitative liquid biopsy for treatment monitoring.

Molecular Counting Enables High-resolution Liquid Biopsy Assay
We describe a novel pan-cancer treatment monitoring liquid biopsy assay that quantifies the changes in cell-free tumor DNA levels at single-molecule resolution, without the need for tissue.

 Session Abstract – PMWC 2022 Silicon Valley

Track 6, June 28-30

The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative